Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Declines By 18.8%

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) saw a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 3,860 shares, a decline of 18.8% from the January 15th total of 4,752 shares. Based on an average trading volume of 3,245 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 3,245 shares, the days-to-cover ratio is presently 1.2 days.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PRTC. Persistent Asset Partners Ltd purchased a new stake in PureTech Health in the 2nd quarter worth approximately $29,000. Diadema Partners LP acquired a new position in shares of PureTech Health in the 2nd quarter valued at $126,000. Lansdowne Partners UK LLP acquired a new position in shares of PureTech Health in the 3rd quarter valued at $260,973,000. Finally, Pentwater Capital Management LP boosted its holdings in PureTech Health by 50.0% during the third quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock worth $1,388,000 after buying an additional 25,000 shares in the last quarter. 0.04% of the stock is owned by institutional investors and hedge funds.

PureTech Health Price Performance

PRTC traded up $0.22 during midday trading on Monday, hitting $17.83. 3,624 shares of the company were exchanged, compared to its average volume of 2,178. The company’s 50 day simple moving average is $17.78 and its 200 day simple moving average is $17.49. PureTech Health has a 1-year low of $13.30 and a 1-year high of $20.00.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of PureTech Health in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, PureTech Health presently has a consensus rating of “Sell”.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.